Has Gerald Sokol, MD received payments from drug or device companies?

Yes. Drug and device makers reported $61,014 in general payments to Gerald Sokol, MD across 235 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gerald Sokol, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gerald Sokol, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gerald Sokol, MD

Radiation Oncology · Cleveland, OHNPI 1174590707

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $41,694 of the $61,014 with a category attached, or 68.3%. Sanofi accounts for 78.9% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2019 at $32,690 and has fallen 93.9% since, to $2,010 in 2025. Among radiation oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,014in general payments, 2019–2025

Across 235 payments — averaging $259.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$48K
Apellis Pharmaceuticals, Inc.$3K
Alcresta Therapeutics, Inc.$2K
Regeneron Healthcare Solutions, Inc.$1K
Rigel Pharmaceuticals, Inc.$1K
AVEO Pharmaceuticals, Inc.$941
plus $5K from 42 others

What the payments were for

Consulting fees$7,48912%
Speaking & faculty fees$41,69468%
Travel & lodging$5,2399%
Food & beverage$6,28710%
Education$3051%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	45	$48,115
Apellis Pharmaceuticals, Inc.	4	$2,532
Alcresta Therapeutics, Inc.	1	$1,600
Regeneron Healthcare Solutions, Inc.	2	$1,393
Rigel Pharmaceuticals, Inc.	3	$1,014
AVEO Pharmaceuticals, Inc.	3	$941
GSK	8	$555
Johnson & Johnson(2 entities)	16	$381
Daiichi Sankyo Inc.	3	$363
Merck	13	$309
AstraZeneca(2 entities)	5	$274
Novartis	15	$272
Lilly USA, LLC	5	$271
Gilead(2 entities)	8	$247
Pfizer	9	$223
Beigene USA, Inc.	6	$201
Genmab U.S., Inc.	1	$200
Amgen	10	$184
Bayer	7	$167
GT Medical Technologies, Inc	1	$165
Incyte Corporation	2	$153
Seagen Inc.	9	$134
Sobi, Inc	3	$133
Astellas Pharma US Inc	2	$121
Takeda Pharmaceuticals U.S.A., Inc.	6	$110
Bristol Myers Squibb	5	$91
AbbVie	3	$88
Eisai Inc.	4	$85
EMD Serono, Inc.	5	$85
Springworks Therapeutics, Inc.	3	$73
E.r. Squibb & Sons, L.L.C.	3	$70
Array Biopharma Inc	5	$62
Sumitomo Pharma America, Inc.	3	$57
Tempus AI, Inc	2	$40
Foundation Medicine, Inc.	1	$38
Servier Pharmaceuticals LLC	2	$35
Pharmaessentia USA Corporation	1	$32
Pharmacosmos Therapeutics Inc.	1	$22
Pharmacyclics LLC, An Abbvie Company	1	$21
Fennec Pharmaceuticals, Inc.	1	$20
Telix Pharmaceuticals	1	$20
Exelixis Inc.	1	$18
Jazz Pharmaceuticals Inc.	1	$18
Tactile Systems Technology Inc	1	$18
Dova Pharmaceuticals	1	$17
TG Therapeutics, Inc.	1	$17
GE HealthCare	1	$14
Advanced Accelerator Applications	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$47,730
RELIZORB$1,600
Tavalisse$1,014
FOTIVDA$900
Enhertu$310
ZEJULA$223
EPKINLY$200
GammaTile$165
PEMAZYRE$131
IMFINZI$125
BRUKINSA$125
VERZENIO$122
Trodelvy$122
Rezlidhia$114
BLENREP$113
TRELEGY ELLIPTA$113
KEYTRUDA$113
XTANDI$104

How this compares

$61,014 in reported general payments places this provider in the 95th percentile of 255 radiation oncology providers in Ohio.

See all radiation oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$371,763

Medicare patients

145

Services billed

11,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	11	$210

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Cleveland

Daniel SprattCleveland$86K
Shlomo KoyfmanCleveland$72K
Rahul TendulkarCleveland$26K
Angela Yuanyuan JiaCleveland$20K
Samuel ChaoCleveland$18K
John SuhCleveland$16K
Shauna CampbellCleveland$12K
Haley PerlowCleveland$7K
Sudha AmarnathCleveland$7K
Ryan FecteauCleveland$3K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →